Trials / Completed
CompletedNCT00496353
MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
A Phase I/II Dose Escalation and Proof-of-Concept Study of MK2461 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this phase I portion are; 1) to evaluate the safety and tolerability of MK2461 and 2) to determine the recommended phase 2 dose or doses of MK2461. The purpose of the phase II portion is to evaluate the anti-tumor efficacy of MK2461.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK2461 | MK2461 treatment, bid, 28-day |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-10-01
- Completion
- 2008-11-01
- First posted
- 2007-07-04
- Last updated
- 2015-03-31
Source: ClinicalTrials.gov record NCT00496353. Inclusion in this directory is not an endorsement.